Tonix Pharmaceuticals News

Tonix Pharmaceuticals | ARS: Annual Report to Security Holders

Apr 16 04:50

Tonix Pharmaceuticals | DEF 14A: Definitive information statements

Apr 16 04:40

Tonix Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Apr 6 04:50

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Apr 2 04:43

Tonix Pharmaceuticals | 10-K: Annual report

Apr 2 04:40

Tonix Pharmaceuticals | 424B5: Prospectus

Mar 30 05:33

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering

Mar 30 05:19

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome

Mar 25 21:08

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

Mar 21 21:26

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia

Mar 20 21:52

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024

Mar 19 20:06

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Holding Corp. Announced the Presentation of Additional Efficacy Data from the Phase 3 Resilient Study

Mar 11 20:06

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime Tnx-102 Sl on Ptsd Symptoms and Sleep Quality in Military-Related Ptsd at Four Weeks of Therapy

Mar 7 21:09

Tonix Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer LEDERMAN SETH

Mar 7 06:06

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia

Mar 6 21:08

Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans

Mar 5 21:07

Tonix Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer LEDERMAN SETH

Mar 1 06:15

Tonix Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SAENGER BRADLEY

Mar 1 06:14

Tonix Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SULLIVAN GREGORY M

Mar 1 06:10

Tonix Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer MORRIS JESSICA EDGAR

Mar 1 06:10